CONFERENCE HIGHLIGHTS |
|
There is bipartisan support of payment reform, according to Scott Gottlieb, MD, speaking at yesterday's general session. He said the Sustainable Growth Rate bill—which he believes will pass this year—embraces and codifies payment reform. Read more |
|
Payers want actionable drug trial data to help them make more informed decisions to increase quality and lower costs. Nathan White, of NucleusX Market Access, and Katya Svoboda of Percipient LLC, talked about how payers will apply data in the next three to five years. Read more |
|
Estimated at $1,000 a day, new drugs for hepatitis C (HCV) are a concern for payers. And more drug therapies are in the pipeline. Utilization management controls must be built for net value. In Session SS3 at AMCP today, an expert panel discusses how to improve HCV treatment success rates, and how to use decision-support tools to reduce variability in treatment and optimize costs.
Read more |
|
Pharmacy plan members with specialty drug out-of-pocket costs less than $250 are more likely to start taking their medication than those with higher out-of-pocket costs. This finding is according to a new study presented by Prime Therapeutics. Read more |
|
|
